TABLE 172: NAIVE SVR GENOTYPE 3 WITH CIRRHOSIS: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV24	PR48	1.47 (1.09 to 1.68)	28.65 (5.13 to 39.15)
SOF12 + PR12		1.56 1.04 to 1.73)	34.09 (2.19 to 41.49)
SOF12 + PR12	SOF24 + RBV24	1.04 (0.79 to 1.30)	3.92 (-16.82 to 21.37)
Random effect model	Residual deviance	5.017 vs. 6 data points	
	Deviance information criteria	30.468	
Fixed effect model	Residual deviance	5.032 vs. 6 data points	
	Deviance information criteria	30.458	

Crl = credible interval; DCV = daclatasvir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference;

RR = relative risk; SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.

Nalve Genotype 3 Without Cirrhosis